⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MGNX News
MacroGenics, Inc.
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
globenewswire.com
MGNX
Form 8-K
sec.gov
MGNX
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
globenewswire.com
MGNX
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
globenewswire.com
MGNX
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
prnewswire.com
ABBV
ANVS
ACIU
BHF
MGNX
NBIX
UCB
ROTH to Host 5th Annual Healthcare Opportunities Conference on September 29 in New York City
globenewswire.com
ANVS
CRVO
MGNX
MNOV
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
MGNX
Form 8-K/A
sec.gov
MGNX
Form 8-K
sec.gov
MGNX
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
globenewswire.com
MGNX